02:26 AM EDT, 08/06/2026 (MT Newswires) -- Hikma Pharmaceuticals (HIK.L) said Thursday that profit for the first half fell, while revenue rose year over year. Profit attributable to equity holders of the parent company for the six months ended June 30 was $223 million, compared with $238 million a year ago. EPS moved to $1.02 from $1.07. Meanwhile, core attributable profit increased to $277 million from $270 million. Core EPS increased to $1.26 from $1.21 The British multinational drugmaker's revenue was $1.73 billion, compared with $1.66 billion earlier. Meanwhile, the board proposed an interim dividend of $0.38 per share, payable on Sept. 17 to shareholders on record Aug. 14. It paid $0.36 per share a year ago. For full-year 2026, the company affirmed guidance for group revenue to increase between 2% and 4% in constant currency and for group core operating profit to be between $720 million and $770 million.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.